Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. The ...

The new data from Vertex’s phase 1/2 trial of VX-880, presented at the American Diabetes Association (ADA) annual congress in Florida, suggest that the therapy can restore the physiological ...